ACE and COVID-19: After multivariable adjustment, neither ACE inhibitors nor ARBs showed an association with the risk of developing COVID-19 (OR 0.95 [95% CI 0.86 to 1.05] and 0.96 [95% CI 0.87 to 1.07], respectively.